InspireMD's ROE % for the quarter that ended in Mar. 2026 was -110.82%. InspireMD's PB Ratio for the quarter that ended in Mar. 2026 was 1.75.
InspireMD's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -63.33%.
InspireMD ROE % Adjusted to Book Value Related Terms
InspireMD ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for InspireMD's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSPR vs TELA, BDMD, PAVM: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, InspireMD's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where InspireMD's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -63.33% mean?
InspireMD (NSPR) has a ROE % Adjusted to Book Value of -63.33% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InspireMD and its competitors.
Is InspireMD's ROE % Adjusted to Book Value too high?
InspireMD's current ROE % Adjusted to Book Value is -63.33%. Overall, InspireMD has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's ROE % Adjusted to Book Value compare to TELA and BDMD?
InspireMD's ROE % Adjusted to Book Value of -63.33% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InspireMD and its competitors. InspireMD's current ROE % Adjusted to Book Value is -63.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (NSPR) is currently considered Possible Value Trap. The stock's GF Value™ is $1.78, compared to a current price of $0.71 — trading 60% below its estimated fair value. The current ROE % Adjusted to Book Value is -63.33%. InspireMD's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For InspireMD (NSPR), the current ROE % Adjusted to Book Value is -63.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (NSPR) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of $0.71 is trading 60% below its estimated GF Value™ of $1.78.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for NSPR:
ROE % Adjusted to Book Value: -63.33%
GF Value™: $1.78 vs. price of $0.71 (60% below fair value)
No single metric tells the full story. See the NSPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
35GF Score
Get the complete analysis for NSPR
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSPR has been successfully added to your 
